Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Pierre Giglio and Arabinda Das.
Connection Strength

1.482
  1. Synergistic Effects of Crizotinib and Temozolomide in Experimental FIG-ROS1 Fusion-Positive Glioblastoma. Cancer Growth Metastasis. 2015; 8:51-60.
    View in: PubMed
    Score: 0.539
  2. Single agent efficacy of the HDAC inhibitor DATS in preclinical models of glioblastoma. Cancer Chemother Pharmacol. 2018 12; 82(6):945-952.
    View in: PubMed
    Score: 0.163
  3. A novel component from citrus, ginger, and mushroom family exhibits antitumor activity on human meningioma cells through suppressing the Wnt/?-catenin signaling pathway. Tumour Biol. 2015 Sep; 36(9):7027-34.
    View in: PubMed
    Score: 0.129
  4. Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy. Anticancer Res. 2015 Feb; 35(2):615-25.
    View in: PubMed
    Score: 0.127
  5. Current Studies of Immunotherapy on Glioblastoma. J Neurol Neurosurg. 2014 Apr 05; 1(1).
    View in: PubMed
    Score: 0.120
  6. Molecular Targets and Treatment of Meningioma. J Neurol Neurosurg. 2014; 1(1).
    View in: PubMed
    Score: 0.118
  7. Multi-targeted DATS prevents tumor progression and promotes apoptosis in ectopic glioblastoma xenografts in SCID mice via HDAC inhibition. J Neurooncol. 2013 Aug; 114(1):43-50.
    View in: PubMed
    Score: 0.114
  8. Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma. Metab Brain Dis. 2013 Sep; 28(3):355-66.
    View in: PubMed
    Score: 0.112
  9. RIP1 and RIP3 complex regulates radiation-induced programmed necrosis in glioblastoma. Tumour Biol. 2016 Jun; 37(6):7525-34.
    View in: PubMed
    Score: 0.034
  10. Drug resistance in glioblastoma: a mini review. Neurochem Res. 2012 Jun; 37(6):1192-200.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.